Please login to the form below

Not currently logged in
Email:
Password:

BMS/Ono enter extended agreement

Bristol-Myers Squibb and Ono Pharmaceutical have announced an agreement to develop separate therapies for cancer and rheumatoid arthritis

Bristol-Myers Squibb (BMS) and Ono Pharmaceutical have announced an agreement to develop separate therapies for cancer and rheumatoid arthritis.

The agreement involving anti-PD-1 antibody known as BMS-936558/ONO-4538 consists of the expansion of BMS' territorial rights to develop and commercialise it. The drug is an investigational cancer immunotherapy which was created under a collaboration in May 2005 between Ono and Medarex.

When Medarex was acquired by BMS, it also gained the rights to develop and commercialise the anti-PD-1 antibody in North America. These rights have now been extended allowing BMS to develop and commercialise the drug around the world, except in Japan, Korea and Taiwan, where Ono has retained all rights.

The other agreement created is for the co-development and co-commercialisation of Orencia (abatacept) in Japan. The drug is a biologic therapy for the autoimmune disease rheumatoid arthritis, and is indicated for use in patients for whom other therapies have failed.

The agreement covers both the currently approved intravenous (IV) formulation and the subcutaneous (SC) formulation, as well as includes all current and future indications. Bristol-Myers K.K. (BMS's Japanese subsidiary) will distribute and book sales of Orencia IV. Ono will distribute and book the sales of Orencia SC.

21st September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics